These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 10330280)

  • 1. Construction and binding analysis of recombinant single-chain TCR derived from tumor-infiltrating lymphocytes and a cytotoxic T lymphocyte clone directed against MAGE-1.
    Lake DF; Salgaller ML; van der Bruggen P; Bernstein RM; Marchalonis JJ
    Int Immunol; 1999 May; 11(5):745-51. PubMed ID: 10330280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
    Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
    J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer.
    Groeper C; Gambazzi F; Zajac P; Bubendorf L; Adamina M; Rosenthal R; Zerkowski HR; Heberer M; Spagnoli GC
    Int J Cancer; 2007 Jan; 120(2):337-43. PubMed ID: 17066423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide.
    Godelaine D; Carrasco J; Lucas S; Karanikas V; Schuler-Thurner B; Coulie PG; Schuler G; Boon T; Van Pel A
    J Immunol; 2003 Nov; 171(9):4893-7. PubMed ID: 14568970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
    Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
    Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide.
    Salgaller ML; Weber JS; Koenig S; Yannelli JR; Rosenberg SA
    Cancer Immunol Immunother; 1994 Aug; 39(2):105-16. PubMed ID: 7519125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple specificities in the repertoire of a melanoma patient's cytolytic T lymphocytes directed against tumor antigen MAGE-1.A1.
    Romero P; Pannetier C; Herman J; Jongeneel CV; Cerottini JC; Coulie PG
    J Exp Med; 1995 Oct; 182(4):1019-28. PubMed ID: 7561675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12.
    Panelli MC; Bettinotti MP; Lally K; Ohnmacht GA; Li Y; Robbins P; Riker A; Rosenberg SA; Marincola FM
    J Immunol; 2000 Apr; 164(8):4382-92. PubMed ID: 10754339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
    Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
    Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual recognition of a human cytotoxic T-cell clone for melanoma antigens.
    Kubo H; Abe J; Obata F; Nakajima H; Tsunoda M; Ogawa A; Nakayama S; Beck Y; Kohsaka T; Darrow TL; Abdel-Wahab Z; Saida T; Takiguchi M
    Cancer Res; 1996 May; 56(10):2368-74. PubMed ID: 8625313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.
    Chaux P; Luiten R; Demotte N; Vantomme V; Stroobant V; Traversari C; Russo V; Schultz E; Cornelis GR; Boon T; van der Bruggen P
    J Immunol; 1999 Sep; 163(5):2928-36. PubMed ID: 10453041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells.
    Carrasco J; Van Pel A; Neyns B; Lethé B; Brasseur F; Renkvist N; van der Bruggen P; van Baren N; Paulus R; Thielemans K; Boon T; Godelaine D
    J Immunol; 2008 Mar; 180(5):3585-93. PubMed ID: 18292586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines.
    Shilyansky J; Nishimura MI; Yannelli JR; Kawakami Y; Jacknin LS; Charmley P; Rosenberg SA
    Proc Natl Acad Sci U S A; 1994 Mar; 91(7):2829-33. PubMed ID: 7511820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.
    Corbière V; Chapiro J; Stroobant V; Ma W; Lurquin C; Lethé B; van Baren N; Van den Eynde BJ; Boon T; Coulie PG
    Cancer Res; 2011 Feb; 71(4):1253-62. PubMed ID: 21216894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conserved TCR usage by HLA-Cw* 1601-restricted T cell clones recognizing melanoma antigens.
    Farina C; van der Bruggen P; Boël P; Parmiani G; Sensi M
    Int Immunol; 1996 Sep; 8(9):1463-6. PubMed ID: 8921424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of T cell receptor alpha beta variability in tumor-infiltrating lymphocytes in primary and metastatic melanoma.
    Zeuthen J; Birck A; Straten PT
    Arch Immunol Ther Exp (Warsz); 1995; 43(2):123-33. PubMed ID: 8744727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library.
    Chames P; Hufton SE; Coulie PG; Uchanska-Ziegler B; Hoogenboom HR
    Proc Natl Acad Sci U S A; 2000 Jul; 97(14):7969-74. PubMed ID: 10884427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus.
    Karanikas V; Lurquin C; Colau D; van Baren N; De Smet C; Lethé B; Connerotte T; Corbière V; Demoitié MA; Liénard D; Dréno B; Velu T; Boon T; Coulie PG
    J Immunol; 2003 Nov; 171(9):4898-904. PubMed ID: 14568971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
    Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
    J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1.
    Sensi M; Traversari C; Radrizzani M; Salvi S; Maccalli C; Mortarini R; Rivoltini L; Farina C; Nicolini G; Wölfel T
    Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5674-8. PubMed ID: 7777568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.